Memorial Sloan Kettering Cancer Center

Ide-cel demonstrated ideal quality of life and similar efficacy in real settings. CAR T-cell therapy is expected to expand into community settings beyond academic centers, particularly with advancements in solid tumors like lung and breast cancer. The cost of CAR T therapy is anticipated to decrease as accessibility improves. A 60-year-old woman with multiple myeloma achieved stringent complete response (CR) post-CAR T-cell infusion, highlighting the therapy's potential.

The FDA approved revumenib (SNDX-5613) for relapsed/refractory KMT2A-rearranged acute leukemia, supported by AUGMENT-101 trial data showing 21.2% CR/CRh rate. Revumenib is the first Menin inhibitor for this condition, offering hope to patients with poor prognosis.

Revumenib achieved a 23% CR/CRh rate in relapsed/refractory NPM1-mutated AML, with 64% of responders showing negative MRD status. Syndax plans to file a supplemental NDA for NPM1-mutated AML in H1 2025, following potential FDA approval for KMT2A-rearranged leukemia.

Lung cancer treatment advances include minimally invasive surgery, targeted therapies, immunotherapies, and genetic testing at MSK. New treatments like KRAS inhibitors and TIL therapy show promise. Early detection through screening and innovative methods like E-nose and liquid biopsies aim to improve survival rates.

Precision and personalization in chronic myeloid leukemia (CML) treatment are crucial as the arsenal of tyrosine kinase inhibitors (TKIs) grows. Asciminib, a new STAMP inhibitor, received FDA approval in 2024 for newly diagnosed CML, showing superior efficacy over imatinib and some second-generation TKIs. Long-term data will determine its potential for higher treatment-free remission rates and possibly a cure. Managing CML remains a challenge due to the need for long-term therapy, emphasizing adherence, adverse effect management, and communication between patients and healthcare providers.

FLOT is preferred for localized adenocarcinoma, with radiation not improving outcomes. HER2-positive disease sees advancements with T-DXd combinations and KEYNOTE-811 final OS analysis. Zolbetuximab's FDA approval for CLDN18.2-positive tumors is significant. FLOT combinations show promise, though not all add-ons improve outcomes. HER2 inhibition alone is insufficient due to intrinsic resistance. PD-L1 CPS and MSI-H status influence treatment efficacy. Zolbetuximab's OS improvement in CLD18.2-positive disease is notable, though anti-PD-1 agents may be better for proximal tumors.

ESMO Congress 2024 presentations include: ctDNA clearance linked to better outcomes in bladder cancer patients; AMG 193, a PRMT5 inhibitor, shows promise in MTAP-deleted solid tumors; ipilimumab/nivolumab improves survival in non–clear cell renal cancer; and T-DXd combinations show efficacy in HER2-positive gastric cancers.

Syros Pharmaceuticals' phase III study for tamibarotene in MDS missed primary endpoint; Amgen's stock steady despite analyst report; Adaptimmune reports positive results for lete-cel; Daiichi Sankyo and Astrazeneca submit new BLA for lung cancer treatment; Apollo Therapeutics signs $938 million deal with Sunshine Lake Pharma; study identifies quiescent cancer stem cells in glioblastoma relapse; Modifi Biosciences acquired by Merck for up to $1.3 billion.

Elicio Therapeutics reports Q3 2024 financial results, anticipates AMPLIFY-7P Phase 2 enrollment completion in Q4 2024, with interim DFS analysis in H1 2025. Presented AMPLIFY-7P Phase 1a data at SITC 2024, showing durable T cell responses and antigen spreading in KRAS mutant tumors. Plans to update RFS and OS data from AMPLIFY-201 at 2024 ESMO Immuno-Oncology Congress. Strengthened cash position to support operations beyond the interim analysis.